Ignite Creation Date:
2024-05-05 @ 11:26 AM
Last Modification Date:
2024-10-26 @ 9:07 AM
Study NCT ID:
NCT00044564
Status:
COMPLETED
Last Update Posted:
2014-12-19
First Post:
2002-08-30
Brief Title:
Evaluation of Bay 59-8862 in Patients With Advanced Renal Cell Carcinoma
Sponsor:
Bayer
Organization:
Bayer
Study Overview
Official Title:
An Uncontrolled Phase II Multi Center Trial Evaluating Antitumor Efficacy and Safety of Bay 59-8862 in Patients With Advanced Renal Cell Carcinoma
Status:
COMPLETED
Status Verified Date:
2014-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
In patients with renal cell cancer most frequent methods of treatment include surgery chemotherapy hormonal therapy and immunotherapy Renal cell carcinoma is usually considered to be radioresistant and chemoresistant In patients with metastatic disease the options are limited The taxanes are among the most commonly used class of chemotherapy agents in clinical oncology today but they are not effective in renal cancers the development of Bay 59-8862 targets taxane-resistant tumors and the current protocol is designed to test the safety and efficacy of Bay 59-8862 in patients with advanced renal cell carcinoma
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None